GILEAD SCIENCES, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $29.4 | $28.8 | $27.1 | $27.3 | $27.3 |
| Operating income | $10.0 | $1.7 | $7.6 | $7.3 | $9.9 |
| Net income | $8.5 | $0.5 | $5.7 | $4.6 | $6.2 |
| Cash Flow Statement | |||||
| Free cash flow | $9.5 | $10.3 | $7.4 | $8.3 | $10.8 |
| Dividends | $4.0 | $3.9 | $3.8 | $3.7 | $3.6 |
| Share repurchases | $1.9 | $1.1 | $1.0 | $1.4 | $0.5 |
Shares outstanding 1.2B · Free float 99.9%
Annual filing data through FY ended December 31, 2025; float as of October 8, 2026.
Earnings
Other Coverage
October 14, 2026
Theme Survey
Drug Pricing and PBM Scrutiny: Medicare Rulemaking Gains Detail
October 14, 2026
Deals
Vir Biotechnology to License TCEs to Gilead for $135 Million
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 15, 2026
Theme Survey
Corcept Flags Direct Revenue Hit as IRA Pricing Rules Widen
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back